FindTrial
Sign In

The investigation based on multi-modal magnetic resonance research the mechanism of effects of Heganshuyu Decoction on depressive disorder of liver depression and spleen deficiency type.

The investigation based on multi-modal magnetic resonance research the mechanism of effects of Heganshuyu Decoction on depressive disorder of liver depression and spleen deficiency type.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000473
Enrollment
Unknown
Registered
2026-03-05
Start date
2026-03-15
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Treatment group:Heganshuyu Decoction
Healthy Control Group:None

Sponsors

Beijing Chaoyang Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for depressive disorders in Western medicine and the criteria for "Yu Bing" (Depression) in Traditional Chinese Medicine, specifically Liver Qi Stagnation and Spleen Deficiency syndrome; (2) Aged between 18 and 65 years, both males and females are eligible; (3) Hamilton Depression Rating Scale (HAMD-17 item score) =8 points and =24 points; (4) Intact overall cognitive function, i.e., Mini-Mental State Examination (MMSE) score of 27-30 points; (5) No other diseases or medical history that may cause mental or emotional disorders; (6) No accompanying motor disorders, gait abnormalities, or other functional impairments; (7) The patient has signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with suicidal tendencies, with a HAMD-17 Item 3 score =3; (2) Patients with severe heart, liver, lung, or kidney dysfunction and hematological diseases; (3) Pregnant women, breastfeeding women, and women during menstruation; (4) History of severe drug or alcohol abuse; (5) Patients who have taken neuroleptic agents, hormonal drugs, or contraceptives in the past two weeks, those who have taken any immunosuppressive drugs, and those who are concurrently using other Chinese herbal medicines; (6) Subjects with claustrophobia, metallic implants in the body, or other contraindications for MRI examination; (7) Abnormal cranial anatomy or other clearly defined pathological changes observed during MRI scanning; (8) Subjects who have participated in similar neuroimaging studies within the past month.

Design outcomes

Primary

MeasureTime frame
Hamiton Depression Scale;—

Secondary

MeasureTime frame
Hamilton Anxiety Scale;Cranial MRI;Brief Patient Health Questionnaire-9 (PHQ-9);Pittsburgh Sleep Quality Index (PSQI);Mini-Mental Status Examination Scale;TCM symptom score;—

Countries

China

Contacts

Public ContactLu Mengxin

Beijing Chaoyang Hospital Affiliated to Capital Medical University

lmxstaring@163.com18811508850

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026